Research Article 
The diagnosis of mild cognitive impairment due to Alzheimer‘s disease: Recommendations from the National Institute on Aging-Alzheimer‘s Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling, Paul S. Aisen, Laurel A. Beckett, Laurel A. Beckett, Suzanne Craft, Anne M. Fagan, Takeshi Iwatsubo, Clifford R. Jack, Jeffrey Kaye, Thomas J. Montine, Denise C. Park, Eric M. Reiman, Christopher C. Rowe, Eric Siemers, Yaakov Stern, Yaakov Stern, Maria C. Carrillo, Bill Thies, Marcelle Morrison- Bogorad, Molly V. Wagster and Creighton H. Phelps
Alzheimer`s & Dementia, 2011, 7(3), 270-279. DOI: 10.1016/j.jalz.2011.03.008
Abstract
The National Institute on Aging and the Alzheimer‘s Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer‘s disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.
ASCI-ID: 285-136
Similar Articles
Fluorodeoxyglucose positron emission tomography of mild cognitive impairment with clinical follow-up at 3 years
Alzheimer`s & Dementia, 2010, 6(4), 326-333. DOI: 10.1016/j.jalz.2009.09.005
Cognitive and structural magnetic resonance imaging features of Lewy body dementia and Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(3), 211-218. DOI: 10.1016/j.jalz.2011.04.008
Comparison of International Working Group criteria and National Institute on Aging�Alzheimer‘s Association criteria for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(6), 560-563. DOI: 10.1016/j.jalz.2011.10.008
The basis for disease-modifying treatments for Alzheimer`s disease: The Sixth Annual Mild Cognitive Impairment SymposiumAlzheimer`s & Dementia, 2009, 5(1), 66-74. DOI: 10.1016/j.jalz.2008.10.006
Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trialsAlzheimer`s & Dementia, 2010, 6(5), 367-377. DOI: 10.1016/j.jalz.2010.07.004
Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume lossAlzheimer`s & Dementia, 2010, 6(5), 378-385. DOI: 10.1016/j.jalz.2010.03.014
Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjectsAlzheimer`s & Dementia, 2010, 6(3), 230-238. DOI: 10.1016/j.jalz.2010.03.008
The Alzheimer’s Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomesAlzheimer`s & Dementia, 2010, 6(3), 257-264. DOI: 10.1016/j.jalz.2010.03.002
Addressing population aging and Alzheimer’s disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer’s Disease Neuroimaging InitiativeAlzheimer`s & Dementia, 2010, 6(3), 291-296. DOI: 10.1016/j.jalz.2010.03.009
Atypical event-related potentials in patients with mild cognitive impairment: An identification-priming studyAlzheimer`s & Dementia, 2010, 6(4), 351-358. DOI: 10.1016/j.jalz.2009.05.664
Association of C-reactive protein with mild cognitive impairmentAlzheimer`s & Dementia, 2009, 5(5), 398-405. DOI: 10.1016/j.jalz.2009.01.025
Outcome over seven years of healthy adults with and without subjective cognitive impairmentAlzheimer`s & Dementia, 2010, 6(1), 11-24. DOI: 10.1016/j.jalz.2009.10.002
A European perspective on population studies of dementiaAlzheimer`s & Dementia, 2011, 7(1), 3-9. DOI: 10.1016/j.jalz.2010.12.003
Operationalizing diagnostic criteria for Alzheimer‘s disease and other age-related cognitive impairment–Part 2Alzheimer`s & Dementia, 2011, 7(1), 35-52. DOI: 10.1016/j.jalz.2010.12.002
Sources of variability in estimates of the prevalence of Alzheimer‘s disease in the United StatesAlzheimer`s & Dementia, 2011, 7(1), 74-79. DOI: 10.1016/j.jalz.2010.11.006
The measurement of everyday cognition: Development and validation of a short form of the Everyday Cognition scalesAlzheimer`s & Dementia, 2011, 7(6), 593-601. DOI: 10.1016/j.jalz.2011.02.007
Functional deficits among patients with mild cognitive impairmentAlzheimer`s & Dementia, 2011, 7(6), 611-614. DOI: 10.1016/j.jalz.2010.12.011
Mild cognitive impairment: Disparity of incidence and prevalence estimatesAlzheimer`s & Dementia, 2012, 8(1), 14-21. DOI: 10.1016/j.jalz.2011.01.002
Cognitive impairment in nondemented oldest-old: Prevalence and relationship to cardiovascular risk factorsAlzheimer`s & Dementia, 2012, 8(2), 87-94. DOI: 10.1016/j.jalz.2011.02.008
Fornix integrity and hippocampal volume predict memory decline and progression to Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(2), 105-113. DOI: 10.1016/j.jalz.2011.05.2416
An investigation of PreMCI: Subtypes and longitudinal outcomesAlzheimer`s & Dementia, 2012, 8(3), 172-179. DOI: 10.1016/j.jalz.2011.03.002
Serum antibodies to periodontal pathogens are a risk factor for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(3), 196-203. DOI: 10.1016/j.jalz.2011.04.006
The epidemiology of Alzheimer‘s disease: Laying the foundation for drug design, conduct, and analysis of clinical trialsAlzheimer`s & Dementia, 2012, 8(3), 237-242. DOI: 10.1016/j.jalz.2011.12.005
Comparing new templates and atlas-based segmentations in the volumetric analysis of brain magnetic resonance images for diagnosing Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(5), 399-406. DOI: 10.1016/j.jalz.2011.07.002
A new informant-based questionnaire for instrumental activities of daily living in dementiaAlzheimer`s & Dementia, 2012, 8(6), 536-543. DOI: 10.1016/j.jalz.2011.08.006
Computer-related self-efficacy and anxiety in older adults with and without mild cognitive impairmentAlzheimer`s & Dementia, 2012, 8(6), 544-552. DOI: 10.1016/j.jalz.2011.12.008
The economics of mild cognitive impairmentAlzheimer`s & Dementia, 2013, 9(1), 58-62. DOI: 10.1016/j.jalz.2012.05.2117
Phenotypic regional functional imaging patterns during memory encoding in mild cognitive impairment and Alzheimer's diseaseAlzheimer`s & Dementia, 2013, 9(3), 284-294. DOI: 10.1016/j.jalz.2011.12.006
Mild cognitive impairment in a community sample: The Sydney Memory and Ageing StudyAlzheimer`s & Dementia, 2013, 9(3), 310-317. DOI: 10.1016/j.jalz.2011.11.010
Predictors and outcomes for caregivers of people with mild cognitive impairment: A systematic literature reviewAlzheimer`s & Dementia, 2013, 9(3), 346-355. DOI: 10.1016/j.jalz.2012.01.012
Long–term anticholinergic use and the aging brainAlzheimer`s & Dementia, 2013, 9(4), 377-385. DOI: 10.1016/j.jalz.2012.02.005